AbbVie

BeiGene has a total of three marketed proprietary products.

FAST NEWS: Beigene stock falls after Novartis terminates partnership

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BGNE.US 6160.HK
BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.

Sales success comes with side effects for drug maker BeiGene

The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
BGNE.US 6160.HK

Recent Articles

RELATED ARTICLES

  1. BeiGene
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
  2. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  3. Cancer drug maker Genfleet joins Hong Kong IPO influx
  4. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  5. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  6. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  7. Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva